Veraxa Collaborates With Ardigen to Use AI for Cancer Drug Development
MT Newswires Live
Jul 13
Veraxa Biotech (VRXA) said Monday it is collaborating with Ardigen to use artificial intelligence to advance its BiTAC cancer therapy pipeline.
The partnership will initially focus on developing AI tools to identify and prioritize dual-target combinations for Veraxa's bispecific T-cell engagers and antibody-drug conjugates, it said.
The company said its BiTAC platform uses an "AND-gate" approach that activates when two cancer targets are present on the same cell, a strategy designed to reduce off-target toxicity and improve treatment precision.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.